SHR-1918
1 paper2 findings
- 1 lab in 1 country
- Funder: Jiangsu Hengrui Medicine
- 2 of 2 findings with company ties
- Human trial1
Outcomes
2Triglyceride
downin humans1
1 study
Triglyceride
downin humans1
SHR-1918 decreases triglyceride in humans (-48.6% (600 mg) to -57.6% (1,200 mg) vs placebo).
Human trialpatients with hyperlipidemia suboptimally controlled after statin run-in600 or 1,200 mg24 weeksn = 44
JACC. Asia3 Sep 2026
LDL-C
downin humans1
1 study
LDL-C
downin humans1
SHR-1918 decreases LDL-C in humans (-18.6% (600 mg) to -22.9% (1,200 mg) vs placebo).
Human trialpatients with hyperlipidemia suboptimally controlled after statin run-in600 or 1,200 mg24 weeksn = 44
JACC. Asia3 Sep 2026
Latest
1 in 12 monthsJACC Asia
Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia
Randomised trial in 44 peopleHyperlipidemia